

S The Global Fund



Africa Regional TB summit

4-6 March, 2019 | Kigali, Rwanda

Theme: It's time for Africa to step up efforts to find all missing people with TB



UNHLM Targets and Regional Context


Jacob Creswell Head, Innovations and Grants Stop TB Partnership

4 March 2019, Kigali



Stop B Partnership

TB care currently leaves behind a large number of people



- Only half (52%) of the estimated people who developed TB are successfully treated
- Only 1 in 7 people estimated to develop DR-TB are successfully treated

Source: WHO's global tuberculosis database, October 2018

Opportunity, 2019 UNCA Political Declaration on the fight against TP

UNHLM ON TB KEY TARGETS FOR 2022

WE, HEADS OF STATE AND GOVERNMENT AND REPRESENTATIVES OF STATES AND GOVERNMENTS ASSEMBLED AT THE UNITED NATIONS IN NEW YORK ON 26 SEPTEMBER 2018':



COMMIT TO PROVIDE DIAGNOSIS AND TREATMENT

with the aim of successfully treating 40 million people with tuberculosis by 2022.

COMMIT TO PROVIDE DIAGNOSIS AND TREATMENT

with the aim of successfully treating 3.5 million children with tuberculosis by 2022.

COMMIT TO PROVIDE DIAGNOSIS AND TREATMENT

with the aim of successfully treating 1.5 million people with drug-resistant tuberculosis, including 115 000 children with drugresistant tuberculosis, by 2022.



COMMIT TO PREVENT TUBERCULOSIS

for those most at risk of falling ill so that at least 30 million people, including 4 million children under five years of age, 20 million other household contacts of people affected by tuberculosis, and 6 million people living with HIV, receive preventive treatment by 2022.

by 2022. 6 COMMIT TO MOBILIZE SUFFICIENT AND

COMMIT TO MOBILIZE

for universal access to

treatment and care of

SUSTAINABLE FINANCING

quality prevention, diagnosis,

tuberculosis, from all sources.

overall global investments for

ending tuberculosis reaching

at least US\$13 billion a year

with the aim of increasing

SUFFICIENT AND

SUSTAINABLE FINANCING FOR R&D with the aim of increasing overall global investments to US\$2 billion, in order to close the estimated US\$1.3 billion gap in funding annually

for tuberculosis research,

contribute appropriately to

research and development.

ensuring all countries

PROMOTE AND SUPPORT AN END TO STIGMA AND ALL FORMS OF DISCRIMINATION,

including by removing discriminatory laws, policies and programmes against people with tuberculosis, and through the protection and promotion of human rights and dignity.

Recognize the various sociocultural barriers to tuberculosis prevention, diagnosis and treatment services, especially for those who are vulnerable or in vulnerable situations, and the need to develop integrated, people-centred, community-based and gender-responsive health services based on human rights.



COMMIT TO DELIVERING. AS SOON AS POSSIBLE, NEW, SAFE, EFFECTIVE, EQUITABLE, AFFORDABLE, AVAILABLE VACCINES,

point-of-care and child-friendly diagnostics. drug susceptibility tests and safer and more effective drugs and shorter treatment regimens for adults, adolescents and children for all forms of tuberculosis and infection, as well as innovation to strengthen health systems such as information and communication tools and delivery systems for new and existing technologies. to enable integrated people-centred prevention, diagnosis, treatment and care of tuberculosis.



REQUEST THE DIRECTOR-GENERAL OF THE WORLD HEALTH ORGANIZATION TO CONTINUE TO DEVELOP THE MULTISECTORAL ACCOUNTABILITY FRAMEWORK

and ensure its timely implementation no later than 2019.



FURTHER REQUEST THE SECRETARY GENERAL WITH THE SUPPORT OF THE WORLD HEALTH ORGANIZATION, TO **PROVIDE A PROGRESS REPORT IN 2020**

10

-

Stop B Partnership

→ END TB

on global and national progress, across sectors, in accelerating efforts to achieve agreed tuberculosis goals, which will serve to inform preparations for a comprehensive review by Heads of State and Government at a high-level meeting in 2023.

UNHLM ON TB KEY COMMITMENTS

WE. HEADS OF STATE AND GOVERNMENT AND REPRESENTATIVES OF STATES AND GOVERNMENTS ASSEMBLED AT THE UNITED NATIONS IN NEW YORK ON 26 SEPTEMBER 2018

REACH ALL PEOPLE BY CLOSING THE GAPS ON TB DIAGNOSIS. TREATMENT AND PREVENTION

P24: 'Commit to providing diagnosis and treatment with the aim of successfully treating 40 million people with tuberculosis from 2018 to 2022. including 3.5 million children, and 1.5 million people with drug-resistant tuberculosis including 115,000 children...' P25: 'Commit to preventing tuberculosis for those most at risk of falling ill through the rapid scaling up of access to testing for tuberculosis infection, according to the domestic situation, and provision of preventive treatment, with a focus on high-burden countries, so that at least 30 million people, including 4 million children under 5 years of age, 20 million other household contacts of people affected by tuberculosis, and 6 million people living with HIV, receive preventive treatment by 2022

TRANSFORM THE TB RESPONSE TO **BE EQUITABLE, RIGHTS-BASED AND PEOPLE-CENTERED**

P14: '...affirm that all these people [affected by TB] require integrated people-centred prevention, diagnosis, treatment, management of side effects, and care, as well as psychosocial, nutritional and socioeconomic support for successful treatment, including to reduce stigma and discrimination." P17: '...in order to make the elimination of tuberculosis possible, prioritizing, as appropriate, notably through the involvement of communities and civil

hosted by

society and in a non-discriminatory manner, high-risk groups and other people who are vulnerable or in vulnerable situations, such as women and children, indigenous peoples, health-care workers, migrants, refugees, internally displaced people, people living in situations of complex emergencies, prisoners, people living with HIV, people who use drugs, in particular those who inject drugs, miners and others exposed to silica. the urban and rural poor, underserved populations, undernourished people, individuals who face food insecurity, ethnic minorities, people and communities at risk of exposure to bovine tuberculosis, people living with diabetes, people with mental and physical disabilities, people with alcohol use disorders, and people who use tobacco, recognizing the higher prevalence of tuberculosis among men." P18: 'Recognize the various sociocultural barriers to tuberculosis prevention diagnosis and treatment services, especially for those who are vulnerable or in vulnerable situations, and the need to develop integrated, people-centred, community-based and genderresponsive health services based on human rights.

P19: 'Commit to promoting access to affordable medicines, including generics, for scaling up access to affordable tuberculosis treatment, including the treatment of multidrugresistant and extensively drug-resistant tuberculosis, reaffirming the World Trade Organization Agreement on

Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement), as amended, and also reaffirming the 2001 World Trade Organization Doha Declaration on the TRIPS Agreement and Public Health...

P25: 'Commit to... enacting measures to prevent tuberculosis transmission in workplaces, schools, transportation systems, incarceration systems and other congregate settings." P33: 'Commit to developing

community-based health services through approaches that protect and promote equity, ethics, gender equality and human rights in addressing tuberculosis

P34: 'Commit to related improvements in policies and systems on each country's path towards achieving and sustaining universal health coverage, such that all people with tuberculosis or at risk of developing tuberculosis receive the quality, accessible and affordable prevention diagnosis treatment and care services they need without suffering financial hardship, with stewardship of antimicrobials and prevention and infection control, within public and community, including faithbased organizations, and private sector services.

P37: 'Commit to... promote and support an end to stigma and all forms of discrimination, including by removing discriminatory laws, policies and programmes against people with tuberculosis 1

P38: 'Commit to providing special attention to the poor, those who are In addition to the ten headline targets, these are some of the key commitments in the Political Declaration, grouped according to the Key Asks (https://bit.ly/2AixuCY) proposed by the TB community. The full Declaration can be viewed here: https://bit.ly/20ylPnA

vulnerable, including infants, young children and adolescents, as well as elderly people and communities especially at risk of and affected by tuberculosis, in accordance with the principle of social inclusion. especially through ensuring strong and meaningful engagement of civil society and affected communities in the planning, implementation, monitoring and evaluation of the tuberculosis response.

ACCELERATE DEVELOPMENT OF ESSENTIAL NEW TOOLS TO END TB

P42: 'Commit to advancing research for basic science, public health research and the development of innovative products and approaches... including towards delivering, as soon as possible, new, safe, effective, equitable, affordable, available vaccines, point-ofcare and child-friendly diagnostics, drug susceptibility tests and safer and more effective drugs and shorter treatment regimens for adults, adolescents and children for all forms of tuberculosis and infection

P43: 'Commit to create an environment conducive to research and development of new tools for tuberculosis, and to enable timely and effective innovation and affordable and available access to existing and new tools and delivery strategies and promote their proper use, by promoting competition and collaboration

P45: 'Promote tuberculosis research and development efforts aiming to be

needs-driven, evidence-based and guided by the principles of affordability. effectiveness, efficiency and equity and which should be considered as a shared responsibility. In this regard, we encourage the development of new product development partnership models and, for multidrug-resistant tuberculosis, continue to support existing voluntary initiatives and incentive mechanisms that senarate the cost of investment in research and development from the price and volume of sales, to facilitate equitable and affordable access to new tools and other results to be gained through research and development...'

INVEST THE FUNDS NECESSARY TO END TB

P46: 'Commit to mobilize sufficient and sustainable financing for universal access to quality prevention, diagnosis, treatment and care of tuberculosis, from all sources, with the aim of increasing overall global investments for ending tuberculosis and reaching at least 13 billion United States dollars a year by 2022

P47: 'Commit to mobilize sufficient and sustainable financina, with the aim of increasing overall global investments to 2 billion dollars, in order to close the estimated 1.3 billion dollar gap in funding annually for tuberculosis research, ensuring that all countries contribute appropriately to research and development...'

COMMIT TO DECISIVE AND ACCOUNTABLE GLOBAL LEADERSHIP INCLUDING REGULAR UN **REPORTING AND REVIEW**

P48: 'Commit to develop or strengthen. as appropriate, national tuberculosis strategic plans to include all necessary measures to deliver the commitments in the present political declaration including through national multisectoral mechanisms to monitor and review progress achieved towards ending the tuberculosis epidemic, with highlevel leadership, preferably under the direction of the Head of State or Government, and with the active involvement of civil society and affected communities, as well as parliamentarians, local governments, academia, private sector and other stakeholders within and beyond the health sector...

P49: 'Request the Director General of the WHO to continue to develop the multisectoral accountability framework in line with World Health Assembly resolution 71.3 and ensure its timely implementation no later than 2019." P53: 'Also request the Secretary-General, with the support of the WHO, to provide a progress report in 2020 on alobal and national progress, across sectors... which will serve to inform preparations for a comprehensive review by Heads of State and Government at a high-level meeting in 2023.





END



-

UNHLM Targets

People on treatment (2018-2022) - cumulative

- TB: 40 million for TB
- Children with TB: 3.5 million
- MDR-TB: 1.5 million
- Children with MDR-TB: 115,000
- TB Preventive therapy: >30 million
- Targets already broken down by country and year: http://stoptb.org/global/advocacy/unhlm_targets.asp



Key Targets and Commitments

This page contains documents and data related to the UN High-Level Meeting (HLM) on TB key targets and commitments for 2022 and outlined in the UN Declaration on TB

UNHLM on TB - Key Targets and Commitments (English) UNHLM on TB - Key Targets and Commitments (Spanish) UNHLM on TB - Key Targets and Commitments (Arabic) UNHLM on TB - Key Targets and Commitments (Chinese) UNHLM on TB - Key Targets and Commitments (French) UNHLM on TB - Key Targets and Commitments (Russian) Key Targets per Country UNHLM on TB - TB Country Targets UNHLM on TB - Drug-resistant TB Country Targets

UNHLM on TB - Childhood TB Country Targets

UNHLM on TB - Preventive Therapy Targets



TB in the WHO African Region

- 2.5 million incident cases of TB in 2017
- Including 660,000 people with TB/HIV
- Children with TB: 300,000
- DR-TB: 90,000
- TB Preventive therapy: >30 million
- 86% of people with TB know their HIV status
- Region leading the way on preventative therapy scale-up (but room to continue)
- TB treatment coverage is 52% as a region
- Diagnosing 40% of DR TB among notified case
- Testing 23% of new cases for RR (S Africa)

 \rightarrow


UNOPS

• A number of countries have turned around declining notification rates

WHO Member State	5		47	· .
STRATE OF THE MERCE, 210	£			ŧ
	-	MT PRI	0.00100000000	Contraction of the local division of the loc
Montality introduction HIV +TED	413 (348-496)		03-440	
Morsality 640416 only1	252 (219-287)		(23-27)	1
Incidence Encludes HIV+TE	2488-0298-276		011-263	
Incidence GRV+TD only1 Incidence (MCR/RSI-TD ^A	443 (SBE-TKT) 90 (TK-1044	63	(7.2-10)	- 1
ROOMED MUNICIPALITY	YE USE TANK	14	11.4-110	
ISTRATIO TO RECEIPTIST OF ASS	AND SAL (TREESAMPS)	10.00		L 1
P111		Turk B	118.	
Females 541 (117			NET CTVID-1 DISED	
Males %4 (12)			48-0 210-1 77E	
Total 2%(2)	119811	VID-24M0 21	480 (2 210-2 TVD	•
TO CASE INTERFERENCES, 2017				1
Total cases notified			1 222 450	-
Total new and relapse			1 294 321	
- % with known HV state	a		BAN	
 — % putmonuty — % bacteriologically con 	trad process of the	10.00	BAN	
			50 N	
MINISTER CALTURNING	I SICOL PETERION			
Til meannen og erage bodh	ed/estimused incide	ncal, 2017	52% 0(7-58	8
Till panlemix facing cataxroph	ic socal costs			
Till cano fasality rasis-levelmus incidence), 2017	ed monual ty/eastru	and	0.27 (0.23-0.21)	8
THE CASE MINISTAND DRAFT	S TO MITCHIN, MIT			1
		-	3/	
Padence with known HIV-acar		the 244.0%	37%	-
Padents with known HIV-star — on amirecrovical dierap			27%	
- ce antineroviral derap		the 244.0%	37%	and and and and
	9 1	244 B92 298 415	27% 89%	
— ce antineroviral derap	9 1	the 244.0%	27% 89%	
- on antinerroyinal therap IIII - exception (444) and Exclimined HURV/RR-TR cases among toolfed palmonary TR	8772333	244 B92 298 415	27% 87%	Concession of the local division of the loca
- on antinensylval therap INNE-INSERVICE TO CARE AND Excimuted MCRU SR-TR cases arroug notified pulmonary TO Excimuted % of TR cases	8772333	244 B92 298 415	2 27% 87% 27 000 27 000 27 000 C/5 000-42 000	
- on antiremovical therap 	87 (2003) 1 (2005) 2.7% (1.3–42)	145 12.47-42	27% 87% 27% 27 000 27 000 27 000 27 000	Not below and a spectrum
- on antiretraviral decay III.4 ISSER UNITIALS, 200 Estimated HERVISS-TEcases among notified pulmonary TE Continuant & Ar TE Cases with MERVISS-TE X notified seared for rithampion moticance	9 807280 12300 2.7% (1.3-40 2.2%	144 244 25 298 42 145 12 49 42 145 12 49 42 42%	2 27% 8 89% 27 900 27 900 (35 000-42 000 0 282 443	Contract and and
 on antimetry-ball deer ap Else A Section 11 (ALC 2010) Excitmant MERV 58-178 common antimetry of 18 common 19 Excitmant % of 18 common 19 Excitmant % of 18 common 19 With MERV 58-78 King 19 common 19 Filterspice resolutions March 20 common 19 common 19 common 19 common 19 Filterspice resolutions 	9 807280 12300 2.7% (1.3-40 2.2%	144 244 252 298 425 145 1249 425 145 1249 425 425 125 1249 429	2 27% 89% 29 200 0 282 443 2 443 2 443	The last state in the
- on aminestrativital duerage III - III - IIII - IIII - IIII - IIII Excinate di MERV 58-78 canes among tonfiled palmonary TE Caternane V & TB canes with MEV 59-78 % nonlined anome for "Complete overlaamone" MEW 191-18 canes seared for Laboratory: combinance	у влужна 1 самя 2.7% (1.3–4) 22% градицанся в ынсале	No. 244 85: 298 455 No. 8057 No. 10 2 MS 12,49-42 42% Filte drugs HISURE TIL 2:	0 27% 8 89% 29% 25 080-42 000 0 2822 442 2 845, 5230-112 845	The last state in the last
- on aminestrativital duerage III - III - IIII - IIII - IIII - IIII Excinate di MERV 58-78 canes among tonfiled palmonary TE Caternane V & TB canes with MEV 59-78 % nonlined anome for "Complete overlaamone" MEW 191-18 canes seared for Laboratory: combinance	у влужна 1 самя 2.7% (1.3–4) 22% градицанся в ынсале	No. 244 85: 298 455 No. 8057 No. 10 2 MS 12,49-42 42% Filte drugs HISURE TIL 2:	2 27% 89% 29 200 0 282 443 2 443 2 443	and below the second second
- on aminestrativital duerage III - III - IIII - IIII - IIII - IIII Excinate di MERV 58-78 canes among tonfiled palmonary TE Caternane V & TB canes with MEV 59-78 % nonlined anome for "Complete overlaamone" MEW 191-18 canes seared for Laboratory: combinance	т влясания 2.7% (1.7-4) 22% газывался в ынсали 4	No. 244 85: 298 455 No. 8057 No. 10 2 MS 12,49-42 42% Filte drugs HISURE TIL 2:	0 27% 8 89% 29% 25 080-42 000 0 2822 442 2 845, 5230-112 845	and below the second second
- os antiverselval therap os antiverselval therap summer to the second second second summer to the second	N RN 2283 Icanes 2.7% (7.3-4) 27% 7% 7% 7% 7% 7% 7% 7% 7% 7% 7% 7% 7% 7	1940 244 052 276 455 276 455 1940 0000 1940 195 1940 0000 1940 195 4575 1950 1950 195 1950 1950 195 195	2 27% 8 87% 77 000 05 000-42 000 9 282 443 2 420 2 421 2 421	and and the second second second
— os antiversavial therap unit-postante its CARC, alto anti-postante its CARC, alto Exclorement MERV (28-76 canon antivers testinder postantesavi testinder antibiotic antibi	ny ETF (2.873 2.7% (7.5-4) 2.7% 793/scance & second 2/ cm (7.5 %) assert in 2015	 See 244 8% 298 855 298 855	0 27% 89% 29% 29% 29% 29% 29% 29% 29% 29% 29% 2	And a
- os antiverselval therap solution of the solution of the solution solution of the solution of the solution of the solution of th	9 879 2283 1caans 2.7% (1.3-4) 22% 72% 72% 74 74 75 76 76 76 76 76 76 76 76 76 76	244 8% 298 85 145 12 49 45 145 12 49 45 145 12 49 45 1	2 27% 8 87% 2 87% 2 87% 2 87% 2 900 2 7000 2 800-42 000 0 2 824 422 2 100 2 846, 2010-101-62 2 100, 3280-102-620 8 8000 8 80000 8 8000 8 8000 8 8000 8 8000 8 8000000 8 80000 8 800000000	concrete from the local sector spectrum
— os antiversivial der ag anti-scort is (1914) (-) (-) Subscort is (1914) (-) (-) Subscort is (1914) (-) (-) Subscort is (1914) (-)	9 879 (2003) 1 (2389) 2 796 (0.3-4) 2 796 (0.3-4) 2 796 798 (0.3-4) 2 796 798 (0.3-4) 2 796 798 (0.3-4) 2 796 (0.3-	244 972 298 45 298 45 298 45 145 12.45 43 145 12.45 43 43% 23% 23% 25% 43% 25% 43% 25% 45% 45% 45% 45% 45% 45% 45% 45% 45% 4	2 27% 8 9% 2 9% 2 9 300 2 4 52 2 5 52 2 4 52 2 4 52 2 5 55 2 5 75 2 5 55 2 5 75 2 5 55 2 5 75 2 5 55 2 5 75 2 5 55 2 5 77 2	and
- os antiverselval therap status and MEM USE-TE causes samong norther pathonauxy TO Solitonand & of TE cause samong norther pathonauxy the MEM USE-TE with MEM USE-TE Northerap and the Telangical maistance MEM USE-TE Laboratory confirmed cause Telanovary cause telanovary	errors and a construction of a	the 244 957 298 455 709 455 700 455 70	2 27% 8 87% 2 87% 2 87% 2 87% 2 900 2 7000 2 800-42 000 0 2 824 422 2 100 2 846, 2010-101-62 2 100, 3280-102-620 8 8000 8 80000 8 8000 8 8000 8 8000 8 8000 8 8000000 8 80000 8 800000000	tarmateriarian and an and an and
- os antiverselval therap status estatus (1924) Satinaand (HSV 1935-18 caans annong nosilikel pathonoury (1) Satinaand (4) The Caans with MSV 193-18 Antifield maskando franzelski naskando Nationaand (4) The Caans with MSV 193-18 Satinaand (4) The Caans New and relapant' caans region New and relapant' caan	errestore 27% (1.5-6) 22% restances to ancore de content to 20% anding retupos, regis as, regissered to 20% anding retupos, regis second-to a 20%	the 244 957 298 455 709 455 700 455 70	0 20% 8 8% 2 8% 2 8% 2 9% 2 8% 2 9 00 2 82 442 3 420 3 7 3 7 3 7 3 7 3 7 3 7 3 7 3 7	tarman and the second
— on antiverselvial therap unit-bismut (HEV) (2014) Extension (HEV) (2014) Tarans among norther pathonicary (1) Extension (4) of HE Cases with MEV (2014) Taransis of the Cases with MEV (2014) Taransis surged for champion makazare MEV) (2014) Taransis surged for Labor array confirmed cases Patents accurate on meaners and therap confirmed cases pathon array confirmed cases and the start space (2014) (2) Mean and cases are space in the start space (2014) (2) Mean and the pathon (2) (2) Mean and the start space (2) Mean and (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2)	errestore 27% (1.5-6) 22% restances to ancore de content to 20% anding retupos, regis as, regissered to 20% anding retupos, regis second-to a 20%	the 244 957 298 455 709 455 700 455 70	0 20% 8 8% 2 8% 2 8% 2 9% 2 8% 2 9 00 2 82 442 3 420 3 7 3 7 3 7 3 7 3 7 3 7 3 7 3 7	tarman and the second
— on antiversavial therap and associated BCAVES-TR cause among nonline (pathworks) TR Contensant & AVES-TR cause among nonline (pathworks) TR Contensant & AVES-TR Net and the Cause with NAVES-TR Net and the Cause second for information and the Cause MERE 181-TR cause second for the Cause and the Cause MERE 181-TR cause second for the Cause and the Cause MERE 181-TR cause second for the Cause and the Cause and the Cause and the Cause and the Cause and the Cause and the the Cause and the Cause and the Cause and the the Cause and the Cause and the Cause and the the Cause and the Cause and the Cause and the the Cause and the Cause and the Cause and the the Cause and the Cause and the Cause and the the Cause and the Cause and the Cause and the Cause and the the Cause and the Cause and the Cause and the Cause and the the Cause and the Cause and the Cause and the Cause and the the Cause and the Cause and the Cause and the Caus	9 ECANAR 2.7% (1.5–6) 22% 22% 22% 22% 22% 22% 22% 22	244 92 244 92 298 215 298 215 1428 92.47-43 10 1428 92.47-43 10 278 1-278 47-43 1428 122 278 1428 122 12 1429 12 14 1429 12 14 14 14 14 14 14 14 14 14 14 14 14 14	1 27% 49% 49% 49% 49% 49% 49% 49% 49% 49% 49	Transmission and the second second second second
— on antiversevial therap and a service seviral (2014), and an experiment (2014) (2014), and anti-several (2014), and antisent (2014) (2014), and antisent (2014), and antisen	y strates stra	the 244 55 298 45 298 45 Am enut rea to 2 145 52,47–43 145 52,47–43 4276 4276 52 122,57 4276 52 122,57 4276 52 122,57 4276 52 122,57 4276 52 122,57 4276 52 122,57 4276 52 122,57 4276 52,57 122,57 4276 52,57 122,57 4276 52,57 122,57	1 27% 49% 49% 49% 49% 49% 49% 49% 49% 49% 49	Transmission and the second
— on antiversavial therap and associated BCAVES-TR cause among nonline (pathworks) TR Contensant & AVES-TR cause among nonline (pathworks) TR Contensant & AVES-TR Net and the Cause with NAVES-TR Net and the Cause second for information and the Cause MERE 181-TR cause second for the Cause and the Cause MERE 181-TR cause second for the Cause and the Cause MERE 181-TR cause second for the Cause and the Cause and the Cause and the Cause and the Cause and the Cause and the the Cause and the Cause and the Cause and the the Cause and the Cause and the Cause and the the Cause and the Cause and the Cause and the the Cause and the Cause and the Cause and the the Cause and the Cause and the Cause and the the Cause and the Cause and the Cause and the Cause and the the Cause and the Cause and the Cause and the Cause and the the Cause and the Cause and the Cause and the Cause and the the Cause and the Cause and the Cause and the Caus	y strates stra	the 244 55 298 45 298 45 Am enut rea to 2 145 52,47–43 145 52,47–43 4276 4276 52 122,57 4276 52 122,57 4276 52 122,57 4276 52 122,57 4276 52 122,57 4276 52 122,57 4276 52 122,57 4276 52,57 122,57 4276 52,57 122,57 4276 52,57 122,57	1 27% 8 9% 9% 9% 9% 9% 9% 9% 9% 9% 9% 9% 9% 9%	Transmission and the second
— on antiversevial therap and a service seviral (2014), and an experiment (2014) (2014), and anti-several (2014), and antisent (2014) (2014), and antisent (2014), and antisen	y strates cases cases control cases contro	the 244 95 298 45 298 45 Am enut reacting 145 12 45 - 43 145 12 45 - 43 4276 4276 12 - 276 4276 445 12 45 - 12 - 27 4276 445 12 45 12 - 27 4276 457 12 - 27 4276 457 12 - 27 4276 457 12 - 27 14 457 12 - 27 14 457 12 - 27 14 457 12 - 27 14 457 12 - 27 14 457 12 - 27 14 457 12 - 27 14 457 12 - 27 14 457 12 - 27 14 457 12 - 27 14 457 12 - 27 14 457 12 - 27 14 457 12 - 27 14 457 12 - 27 15 457 12 - 27 14 457 12 - 27 14 457 12 - 27 14 457 12 - 27 14 457 12 - 27 14 457 12 - 27 14	1 27% 8 9% 9% 9% 9% 9% 9% 9% 9% 9% 9% 9% 9% 9%	Transmission and the second
— on antiversavial therap and according to CATA and another sector and the CATA and another sector and the CATA and another sector and the CATA and another sector and the comparison was and the compariso	9 8722103 I CAMPA 2.7% (7.3–6) 22% 723% 725% 72	the 244 95 298 45 298 45 Am enut reacting 145 12 45 - 43 145 12 45 - 43 4276 4276 12 - 276 4276 445 12 45 - 12 - 27 4276 445 12 45 12 - 27 4276 457 12 - 27 4276 457 12 - 27 4276 457 12 - 27 14 457 12 - 27 14 457 12 - 27 14 457 12 - 27 14 457 12 - 27 14 457 12 - 27 14 457 12 - 27 14 457 12 - 27 14 457 12 - 27 14 457 12 - 27 14 457 12 - 27 14 457 12 - 27 14 457 12 - 27 14 457 12 - 27 15 457 12 - 27 14 457 12 - 27 14 457 12 - 27 14 457 12 - 27 14 457 12 - 27 14 457 12 - 27 14	1 27% 8 9% 9% 9% 9% 9% 9% 9% 9% 9% 9% 9% 9% 9%	Transmission (1995) (1995)
— on antiversavial therap and according to CATA and another sector and the CATA and another sector and the CATA and another sector and the CATA and another sector and the comparison was and the compariso	y strate strate strate y strate str	ohen 2.64.852 2008.813 2008.813 Alem ensurt reaction 4.25% 14.35% 6.25% Media Participant 4.25% Media Partitipant 4.25%	1 27% 197%	Transmission (1995) (1995)
— on antiverselvial therap and a series and the Calif, and Estimated MISV 283-78 causes among nodified patheneousy 10 faithmand of 7 Microsoft and with MISV 283-78 A notified award for charapter maintained antipies and real and anti- charapter confirmed causes and Microsoft and antipies and management of the Microsoft and Microsoft and antipies and antipies and the patheneous and antipies and the Microsoft and antipies and antipies and real and antipies and antipies and real and and Microsoft and antipies and and antipies and real patheneous and and antipies and real patheneous and and and antipies and antipies and antipies and real patheneous and antipies and antipies and and antipies antipies and antipies and antipies and antipies and antipies and antipies and antipies and antipies and antipies antipies and antipies and antipies and antipies antipies and antipies antipies antipies antipies antipies and antipies antipies and antipies antipies and antipies and antipies antipies and antipies and antipies antipies and antipies and antipies antipies antipies antipies antipies and antipies antipies and antipies antipies and antipies antipies ant	y strate strate strate y strate str	ohen 2.64.852 2008.813 2008.813 Alem ensurt reaction 4.25% 14.35% 6.25% Media Participant 4.25% Media Partitipant 4.25%	1 27% 5 97\% 5 97% 5 97\%\% 5 97\% 5 97\% 5 97\% 5 97\% 5 97\% 5 97\% 5 97\% 5 97\% 5 97\% 5 97\% 5 9	Transmission (1995) (1995)
— on antiverselvial therap and a second of 10 (24% and an experimental to (24% and an experimental to (24% and a second of 10 (24% and a second a second of 10 (24% a second a second a second a second a second a second a second a se	errozers icanes 2.7% (7.5–6) 22% 22% 22% 22% 22% 22% 22% 22	the 244 95 298 45 298 45 145 12,45 - 43 4276 145 12,45 - 43 4276 4276 4276	1 27% 49% 49% 49% 49% 49% 49% 49% 49% 49% 49	Transmission (1995) (1995)
— on antiverselvial therap and a series and the Calif, and Estimated MISV 283-78 causes among nodified patheneousy 10 faithmand of 7 Microsoft and with MISV 283-78 A notified award for charapter maintained antipies and real and anti- charapter confirmed causes and Microsoft and antipies and management of the Microsoft and Microsoft and antipies and antipies and the patheneous and antipies and the Microsoft and antipies and antipies and real and antipies and antipies and real and and Microsoft and antipies and and antipies and real patheneous and and antipies and real patheneous and and and antipies and antipies and antipies and real patheneous and antipies and antipies and and antipies antipies and antipies and antipies and antipies and antipies and antipies and antipies and antipies and antipies antipies and antipies and antipies and antipies antipies and antipies antipies antipies antipies antipies and antipies antipies and antipies antipies and antipies and antipies antipies and antipies and antipies antipies and antipies and antipies antipies antipies antipies antipies and antipies antipies and antipies antipies and antipies antipies ant	y strates iccases 2.7% (7.3~4) 2.7% 2.7% 2.7% 2.7% 2.7% 2.7% 2.7% 2.7%	type 244 852 298 451 298 451 Mart ender freid teil 2 298 451 Mart Na 10, 479 453 427 45 Mart Na 10, 479 453 427 45 Mart Na 10, 479 453 122 71 Mart Na 10, 122 71 12 Mart Na 10, 123 71 12 Mart Na 10, 123 71 12 Mart Na 10, 123 71 12	1 27% 5 97\% 5 97\%\% 5 97\%\% 5 97\% 5 97\% 5 97\% 5 97\% 5 97\% 5 97\% 5 97\% 5 97\% 5 97	tummenterster version and spens


Stop IB Partnership







UNHLM R/MDR TB treatment scale up target



Country targets at: http://stoptb.org/assets/document s/global/advocacy/unhlm/UNHLM %20on%20TB%20-%20Drugresistant%20TB%20Country%20Tar gets.pdf

Action needed: 1. Find all people with TB 2. 100% DST coverage

4 fold increase needed

hosted by

UNHLM DS TB treatment scale up target

UNHLM Targets for 13 HB African Countries 1,600,000 1,400,000 1,200,000 Actual Notifications 1,000,000 800,000 600,000 400,000 200,000 2017 2018 2019 2020 2021 2022



Country targets at: http://stoptb.org/assets/document s/global/advocacy/unhlm/UNHLM %20on%20TB%20-%20Drugresistant%20TB%20Country%20Tar gets.pdf


Action needed: 1. Expand access to care 2. Increase numbers of people tested 3. Involve other actors to reach more people

6.6m cumulative target





UNHLM preventative treatment scale up target



Country targets at: http://stoptb.org/assets/document s/global/advocacy/unhlm/UNHLM %20on%20TB%20-%20Drugresistant%20TB%20Country%20Tar gets.pdf


Action needed: 1. Updates in guidelines 2. Scale up contact investigation 3. Improved case finding From <1 million to 2.6 million

hosted by

Stop IB Partnership

Global Resource Need to achieve 2018 UNGA TB implementation targets (USD Billions)

- 65 billion USD for 2018-2022
- average 13
 billion USD per annum





Global Plan: Current plan is being updated to 2022







Thank You





S The Global Fund



Africa Regional TB summit

4-6 March, 2019 | Kigali, Rwanda

Theme: It's time for Africa to step up efforts to find all missing people with TB